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Abstract
Background: Oesophago-gastric cancer services in England have been extensively reorganised
since 2001 to deliver a centralised, specialist-led service. Our aim was to assess how well the
National Health Service (NHS) in England met organisational standards for oesophago-gastric
cancer care.
Methods: Questionnaires that asked about the provision of staging investigations, curative and
palliative treatments and key personnel were sent in September 2007 to the lead clinician for
oesophago-gastric cancer at all 30 cancer networks and 156 NHS acute trusts in England.
Results: Responses were received from all networks and 81% of NHS trusts. All networks
provided essential staging investigations and a range of endoscopic palliative therapies. Only 16 of
the 30 cancer networks discussed all patients at the specialist multi-disciplinary team meeting and
11 networks had not fully centralised curative surgery. There was also variation between NHS
trusts in the integration of the palliative care team, the availability of nurse specialists and the use
of dieticians to provide nutritional support.
Conclusion: There has been considerable progress in reforming oesophago-gastric cancer
services but the process of reorganisation is still incomplete and regional differences in service
provision exist that may lead to variation in patient outcomes.
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Oesophageal and gastric cancer together represent the
third most common cause of cancer death in the United
Kingdom [1-3]. The prognosis is often poor with overall
5-year survival rates in the United Kingdom being approx-
imately 8% for oesophageal cancer and 14% for gastric
cancer [1,2]. The majority of patients present with
advanced disease and many also have significant comor-
bidity and a poor level of overall fitness. As a result, the
diseases' management, both curative and palliative, is
complex and involves many different professional groups
including surgeons, gastroenterologists, oncologists, pal-
liative care physicians, radiologists, nurse specialists and
dieticians [4-7].
During the 1990s, it was recognised that oesophago-gas-
tric cancer services in England were fragmented and
poorly organised. To overcome these weaknesses, the
National Health Services (NHS) Cancer Plan [8] and the
Improving Outcomes Guidance in Upper Gastro-Intesti-
nal Cancer [5] set out a reform strategy and a number of
specific recommendations. Firstly, all hospitals caring for
cancer patients should be integrated into regional cancer
networks. Within each network, curative services should
be centralised into specialist cancer centres and a system
should be established to coordinate care between these
centres and other network hospitals (designated local
units). Secondly, it was recommended that clinicians
within each hospital should work together as a multi-dis-
ciplinary team (MDT).
The implementation of this reform strategy has seen
oesophago-gastric cancer services undergo an extensive
reorganisation. In this paper, we describe the results of a
survey of English cancer networks and NHS acute trusts
carried out in September 2007 that aimed to investigate
the extent to which the reorganisation of oesophago-gas-
tric cancer services had been completed, and to examine
variation in the provision of diagnostic, therapeutic and
support services. We also discuss these findings with the
results of the Cancer Peer Review Programme carried out
by the UK Department of Health between 2004 and 2007.
The survey was performed as part of the National
Oesophago-Gastric Cancer Audit, details of which can be
found in its first annual report [9].
Methods
Data on the organisation of oesophago-gastric cancer
services were collected using two different questionnaires.
The first contained questions that focused on the organi-
sation of services within the cancer networks [see Addi-
tional file 1]. Networks are responsible for developing and
planning all aspects of NHS cancer services within their
region, including the process of centralisation. This
requires coordinating the allocation of resources and
establishing referral pathways between NHS acute trusts
as well as other providers. The second questionnaire con-
tained questions about the individual characteristics of
services within the individual NHS trusts, focussing on the
availability of key health professionals and the delivery of
specific aspects of care [see Additional file 2]. Questions in
both questionnaires were based on the recommendations
in UK guidelines on the organisation of oesophago-gastric
cancer services [5,6,10,11] (Table 1) and covered issues
previously identified as essential for high-quality care [9].
A database of English cancer networks and NHS acute
trusts was prepared by combining information from vari-
ous sources, including the Cancer Services Collaborative
Improvement Partnership and the National Clinical Audit
Support Program. Each network and NHS trust was then
contacted to confirm the name and position of the lead
clinician for oesophago-gastric cancer. The questionnaires
were sent to these lead clinicians in September 2007 and
non-responders were followed up by email and tele-
phone.
Results
Responses were received from all 30 cancer networks and
from 38 of the 44 specialist cancer centres (84%) and
from 88 of the 112 local units (79%). The structure of the
networks are summarised in Table 2.
Cancer networks
The centralisation of oesophago-gastric curative cancer
surgery was reported as still ongoing in 11 of the 30 net-
works. In four of the eleven, this involved centralising the
work of one remaining unit. Services still required major
restructuring in the other seven networks, with the lead
clinicians in four of these reporting that the timescale for
completion of this work was unclear.
The cancer networks identified 59 acute trusts that per-
formed curative surgery for oesophago-gastric cancer. Of
these, 14 (24%) were local units and one network
reported that some patients received surgery in a Welsh
cancer centre. All of the 45 specialist cancer centres and
seven local units performed both oesophageal and gastric
surgery. The seven other local units performed gastric sur-
gery only. There were 152 surgeons working at these 59
acute trusts; 137 (90%) were upper gastrointestinal sur-
geons and 15 (10%) were thoracic surgeons (who worked
at ten of the centres). The number of surgeons working at
individual trusts varied from one to five (Table 3). Seven
local units had a single surgeon and 53% of centres had
three surgeons or more. Visiting surgeons based at local
units carried out curative surgery in 18 specialist cancer
centres.Page 2 of 8
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specialist MDT meeting (i.e. an MDT meeting in a special-
ist cancer centre), while in the remaining networks only
patients who were felt to require specialist input were dis-
cussed at these specialist MDT meetings.
The core staging investigations (CT scan, endoscopic
ultrasound (EUS), laparoscopy) were available in all 30
networks, but access to EUS fine needle aspiration, PET,
and PET-CT scan was variable (Table 4). The networks dif-
fered in terms of whether all or selected patients under-
went particular investigations. Where investigations were
performed in selected cases, the selections were based on
clinical considerations rather than on patients' geograph-
ical location within the network.
Palliative treatment in the form of endoluminal stents and
argon beam coagulation was available in all 30 networks,
laser ablation or photodynamic therapy in 18, and brach-
ytherapy in 16. All but two networks could provide endo-
scopic palliative therapy within two weeks of the decision
to treat. Similarly, access to chemotherapy (both palliative
and curative) could be provided within the same time-
frame by 27 networks and to radiotherapy by 25.
NHS acute trusts
106 of the 126 responding trusts (84%) had palliative care
teams that included both a palliative medicine consultant
and a palliative nurse specialist. Integration of palliative
care into the multidisciplinary process was variable, with
no member of the palliative care team routinely attending
the MDT meetings at 10 of the 38 responding specialist
cancer centres (26%) and 26 of the 88 local units (30%).
The number of clinical nurse specialists (CNS) varied
between trusts. All 38 responding cancer centres had at
least one full-time or two part-time CNS and 18 (47%)
had two or three full-time CNS. Local units had fewer
nurse specialists. Of the 88 responding local units, 15
(17%) had only one part-time CNS and nine had none at
all.
All 38 responding specialist cancer centres and 83 of the
88 local units (94%) were able to provide dietician sup-
port. However, trusts differed in the groups of patients for
whom dietician support was available and in the method
of nutritional assessment made before patients began
their treatment (Table 5). In particular, 33 of the 126
responding trusts (26%) had no dietician support for
Table 1: Published standards on which the survey questionnaires were based
Network questionnaire Trust questionnaire
1. Treatment for patients with oesophageal cancer should be the 
responsibility of Specialist Oesophago-gastric Cancer Teams based in 
Cancer Units or Cancer Centres which would normally serve 
populations of at least one million. (IOG, p45)
1. The specialist palliative care team should be multi-professional, and 
should, as a minimum, include a palliative care physician and palliative 
care nurse specialists. (IOG, p61)
2. There should be 24-hour on-call consultant specialist surgical cover 
for postoperative care. Note: To achieve this measure at least 3 
specialist consultant surgeons per team would be needed. 
(MCS, measure 2F-227)
2. A palliative care specialist should be a member of the Specialist 
Oesophago-Gastric Cancer Team and the Local Upper Gastro-intestinal 
Cancer Care Team. (IOG, p29-31)
3. The stage and spread of the cancer should be assessed using 
computed tomography (CT) or magnetic resonance scanning. If the 
patient is sufficiently fit to undergo radical treatment and imaging 
produces no evidence of widespread or metastatic disease, endoscopic 
ultrasound (EUS) should be used to estimate the depth of tumour 
penetration. If this also suggests that radical treatment could be 
successful, patients whose tumours could involve the peritoneal cavity 
should proceed to laparoscopy. (IOG, p37)
3. From the time of assessment, each patient should have access to a 
named clinical nurse specialist who can offer support and continuity of 
care. (IOG, p32)
4. Laser or photodynamic therapy should be used for initial control of 
obstructive symptoms caused by exophytic tumours in the oesophagus. 
Partially covered self-expanding metal stents should be used to control 
obstructive oesophageal symptoms either following or instead of laser 
therapy, depending on the availability of local expertise. (SIGN, p33-35)
4. Specialist advice should be available from a dietician. This should focus 
on helping patients to achieve adequate nutrition. Patients who have 
undergone surgery for oesophageal or gastric cancer should be given 
guidance to help them deal with post-surgical syndromes which can 
cause problems with eating. (IOG, p21-22)
5. Palliative chemotherapy should start within 2 weeks and ideally within 
48 hours, depending on symptom severity. Chemotherapy with curative 
or adjuvant intent should start within 3 weeks and ideally within 1 week. 
Urgent radiotherapy, e.g., for spinal cord compression or superior vena 
cava obstruction, should start within 24 hours of referral. Palliative 
radiotherapy should start within 2 weeks and ideally within 48 hours, 
depending on symptom severity. Radical radiotherapy should start 
within 4 weeks and ideally within 2 weeks. (RCR)
5. All patients should be screened using a validated screening tool to 
assess nutritional risk. (SIGN, p24)
KEY to references:
SIGN = The Scottish Intercollegiate Guidelines Network (2006) [10]; IOG = Department of Health (2001) [5]; MCS = Department of Health 
(2004) [6]; RCR = The Royal College of Radiologists (2003) [11]Page 3 of 8
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any formal nutritional assessment before starting treat-
ment.
Discussion
Since the publication of the Improving Outcomes Guid-
ance [5], oesophago-gastric cancer services in England
have made considerable progress in developing a central-
ised, specialist service. We found that, in September 2007,
all NHS acute trusts were organised into cancer networks
and patients in all networks had access to the core staging
investigations as well as to a range of palliative treatments.
Coinciding with this reorganisation, the overall survival
of patients with oesophago-gastric cancer has improved,
with 1-year survival increasing from 30% to 37% between
1998 and 2005 [9]. However, we found that some compo-
Table 2: Organisation of NHS oesophago-gastric cancer services in England at the time of the survey
English region Cancer network Number of NHS acute trusts Number of responses from NHS
trusts
Cancer Centres Local Units Total
North Lancashire and South Cumbria 1 3 4 4
North Greater Manchester and Cheshire 3 9 12 11
North Merseyside and Cheshire 2 7 9 6
North Yorkshire 2 5 7 7
North Humber and Yorkshire Coast 1 2 3 3
North North of England 2 7 9 8
East Midlands North Trent 2 3 5 5
East Midlands Arden 1 2 3 3
East Midlands Mid Trent 1 2 3 2
East Midlands Derby/Burton 1 1 2 2
East Midlands Leicestershire, Northamptonshire and 
Rutland
2 1 3 3
West Midlands Pan Birmingham 2 2 4 3
West Midlands 3 Counties 1 2 3 3
West Midlands Greater Midlands 2 3 5 5
East of England Mount Vernon 2 1 3 2
East of England Thames Valley 2 4 6 6
East of England Anglia 2 7 9 5
East of England Essex 1 4 5 2
London West London 1 6 7 4
London North London 1 5 6 2
London North East London 2 3 5 5
London South East London 1 5 6 4
London South West London 1 4 5 3
South East Central South Coast 2 5 7 5
South East Surrey, West Sussex and Hampshire 1 3 4 4
South East Sussex 1 2 3 2
South East Kent and Medway 1 3 4 3
South West Peninsula 1 4 5 5
South West Dorset 1 2 3 3
South West Avon, Somerset and Wiltshire 1 5 6 6
Table 3: Number of surgeons performing oesophago-gastric curative surgery within NHS acute trusts identified by the 30 English 
cancer networks as providing this service
Number of surgeons per trust
1 2 3 4 5
Cancer centres (n = 45) 0
(0%)
21
(47%)
14
(31%)
3
(7%)
7
(16%)
Local units providing oesophageal
and gastric surgery (n = 7)
2
(29%)
5
(71%)
0 0 0
Local units providing gastric surgery
(n = 7)
5
(71%)
2
(29%)
0 0 0Page 4 of 8
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centralisation of curative surgery was still in progress in 11
of the 30 cancer networks. Fourteen local units were still
performing curative surgery and in seven of these, this was
being performed by a single surgeon. Also, in only 16 net-
works were all patients discussed at a specialist MDT
meeting. Moreover, palliative care teams were not fully
represented in about a quarter of the multidisciplinary
teams and some local units did not have a clinical nurse
specialist.
The response rate to our questionnaires was high which
strengthens the representativeness of our findings. There
are three limitations to the study. Firstly, this was a cross-
sectional study so the results do not provide evidence of
change over time. Secondly, respondents provided self-
reported data and we cannot exclude "social desirability
bias" given that the lead clinicians may have wanted to
give favourable answers. However, the likely impact of
this bias is small because most questions addressed facts
rather than perceptions.
Thirdly, the study examined the facilities and policy of
each network, not what actually happens to patients. For
example, while the policy in each network recommended
that all patients being considered for curative treatment
Table 4: Reported availability of staging investigations in the 30 English cancer networks
Investigation Patients on whom the investigation is performed
Tumour site In all patients In selected patients None Missing values
CT scan Oesophageal 28 (93%) 2 (7%)
Junctional 28 (93%) 2 (7%)
Gastric 28 (93%) 2 (7%)
Endoscopic Oesophageal 17 (57%) 13 (43%)
Ultrasound (EUS) Junctional 16 (53%) 14 (47%)
Gastric 3 (10%) 22 (73%) 5 (17%)
Staging Oesophageal 2 (7%) 25 (86%) 2 (7%) 1
Laparoscopy Junctional 12 (41%) 17 (59%) 1
Gastric 19 (66%) 10 (34%) 1
EUS Fine Oesophageal 3 (10%) 20 (67%) 7 (20%)
Needle Junctional 3 (10%) 20 (67%) 7 (20%)
Aspiration Gastric 2 (7%) 17 (57%) 11 (37%)
PET Scan Oesophageal 10 (33%) 17 (57%) 3 (10%)
Junctional 8 (4%) 19 (63%) 3 (10%)
Gastric 2 (7%) 16 (53%) 11 (37%)
PET-CT Oesophageal 7 (23%) 21 (70%) 2 (7%)
Junctional 6 (20%) 22 (73%) 2 (7%)
Gastric 1 (3%) 19 (63%) 10 (33%)
Table 5: Provision of nutritional support to oesophago-gastric cancer patients by the 126 NHS acute trusts who responded to the 
questionnaire
Cancer centres
(n = 38)
Local units
(n = 88)
Patients who have access to a dietician for specialist nutritional advice
Surgical inpatients 28 (74%) N/A
All other Oesophago-Gastric cancer inpatients 34 (89%) 75 (85%)
Outpatients 32 (84%) 72 (82%)
No specialist support available 0 5 (6%)
Methods of formal nutritional assessment prior to treatment
No formal assessment 9 (24%) 32 (36%)
Dietician assessment 26 (68%) 43 (49%)
Formal screening instrument
(e.g. MUST score, Nutritional Risk Index)
3 (8%) 13 (15%)Page 5 of 8
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networks were unknown. Routine activity data could be
used to describe progress in centralisation, but more
detailed evaluation of processes such as disease staging
requires prospective data collection. The National
Oesophago-Gastric Cancer Audit will assess the process
and outcomes of the care received by patients with this
cancer in England and Wales [9].
The results of this "snapshot" survey confirm and comple-
ment those of the National Cancer Peer Review Pro-
gramme that included visits to all cancer networks in
England between November 2004 and March 2007 [12].
The Peer Review programme reported that overall compli-
ance with the upper gastro-intestinal performance meas-
ures was 70%; compliance with a selected number of
measures is shown in Table 6. Our results are more spe-
cific because the Peer Review process examined upper-gas-
trointestinal (upper GI) cancer services, which grouped
oesophago-gastric cancer together with liver, pancreatic
and biliary tract cancer.
Peer Review found that the performance of upper GI can-
cer services was often worse than for other cancer sites. For
example, the overall compliance rate of 70% was below
that of breast, colorectal, lung and gynaecological cancer
(77%, 77%, 73% and 75%, respectively). Similarly,
attendance at the MDT meetings was the worst for any
cancer site except lung with the core MDT membership
present at less than half of the meetings (46% for centres
and 33% for units). This compares to breast (77%), color-
ectal (58%) and gynaecology (83% for centres and 45%
for local units). As in our survey, workforce issues were
flagged up, especially with respect to the provision of clin-
ical nurse specialists and palliative care teams. Overall
upper GI cancer had the worst provision of nurse special-
ists of any cancer site. Compared to other services
involved in the care of all cancer sites (such as oncology,
radiology, etc.), specialist palliative care had the lowest
overall level of compliance on the performance measures.
The Peer Review Programme was undertaken over a three
year period while networks were reorganising their serv-
ices. The reorganisation was supposed to be complete by
the end of 2007 and this may be one reason why Peer
Review found variation in how well the networks com-
plied with the IOG recommendations. Our survey builds
on Peer Review because it took place shortly before the
deadline for full reorganisation. It is concerning that we
found significant variation between networks in their pro-
vision of services, and that many had still not completed
their reorganisation. It is also concerning that a minority
were unable to give a date for completion.
The variation in service provision that we observed has
implications for patient care and highlights several areas
where improvements should be made. Firstly, there is
good evidence that postoperative mortality is lower
[13,14] and long-term survival is higher [15-17] if curative
surgery is performed by high-volume specialist surgical
teams. Over a third of the cancer networks had not com-
pleted the centralisation of curative surgery and just under
half of NHS trusts were not providing 24-hour specialist
consultant surgical cover. Of particular concern are the
seven local units were still providing curative surgery with
just one surgeon. There is a high-risk of complications
after curative surgery and, for high quality postoperative
care, surgeons with specialist knowledge and experience
need to be continuously available.
Secondly, the provision of palliative care services, special-
ist nurses and nutritional support was variable and in a
proportion of NHS trusts was insufficient. Studies have
shown that patients with oesophago-gastric cancer require
Table 6: Key findings of the 2004 - 2007 Peer Review Programme of Upper Gastrointestinal Cancer services in English NHS acute 
trusts [12].
Aspect of care Peer Review results
Referral pathways 55% of the networks had referral guidelines agreed 
for diagnostic referral to secondary care
49% of the networks had guidelines agreed for referrals 
from secondary to tertiary care.
Network structure There were significant gaps across all cancer sites in 
provision of oncologists, pathologists, radiologists, 
palliative medicine consultants and clinical nurse 
specialists.
37% of networks had specialist surgical teams with a 24-
hour on-call rota (i.e. contained a minimum of 3 
surgeons). There was wide regional variation in this from 
13% (East) to 60% (South).
MDT structure Units and centres had established their core MDTs 
in almost 100% of networks. Cover arrangements 
for core members (in case of annual leave etc) 
were in place overall in 58% of centres and 44% of 
units.
46% of cancer centres and 33% of local units achieved 
the standard of core members attending half of the MDT 
meetings
Clinical Nurse Specialist provision The number of clinical nurse specialists per MDT 
was 1.4 for centres and 0.85 for units.
There was no clinical nurse specialist cover in 14% of 
cancer centres and 31% of local units, problems with 
workload and cover were reported in more than 20 
centres and 30 units.Page 6 of 8
(page number not for citation purposes)
BMC Health Services Research 2009, 9:204 http://www.biomedcentral.com/1472-6963/9/204intensive support due to their poor quality of life and high
level of symptoms [18,19]. There is also evidence that
shows that patients who are malnourished have reduced
survival, a worse quality of life [20,21], lower rates of
completion of oncology treatment [22,23] and a higher
rate of postoperative complications [22,23]. Nutritional
support has been shown to reduce the impact of malnutri-
tion and improve many of these outcomes [24]. A quarter
of specialist centres do not formally assess their patients'
nutritional status (either by dietician assessment or by a
validated screening tool) before starting treatment. Sim-
ple tests such as the Nutritional Risk Index can be rapidly
carried out by any doctor or nurse in the outpatients
department and if performed on every patient could have
a meaningful impact on their care.
Thirdly, although overall access to invasive palliative tech-
niques was good with rapid access to stents and argon
ablation therapy being available in all networks, access to
other modalities was poor. Patients had to wait longer
than 2 weeks for palliative chemotherapy in three of the
thirty networks and for palliative radiotherapy in five net-
works. Brachytherapy was only available in 16 networks
despite the fact that, compared to endoluminal stents,
research has shown it to have fewer side-effects and pro-
vide better palliation in patients with an expected survival
of greater than three months [25].
Finally, the Improving Outcomes Guidance recom-
mended that all patients should be discussed by the spe-
cialist MDT [5]. The survey found that this occurs in 16
networks (53%). However, each network was also recom-
mended to develop clinical guidelines on the selection of
patients for referral to the specialist team [5]. The Peer
Review Programme observed that these guidelines were in
place in 71% of networks [11]. Consequently, not all
patients are necessarily receiving the benefit of specialist
experience. Processes need to be established so that each
patient, irrespective of stage of disease or comorbidity, is
evaluated by the network specialist teams, either by for-
mal referral to the specialist MDT meeting or by discus-
sion with a member of the specialist MDT.
Conclusion
Although considerable progress has been made in trans-
forming oesophago-gastric cancer care into a specialist,
multi-disciplinary service, further improvements are nec-
essary. Action is required to rectify the deficits in the pro-
vision of surgery, palliative care, clinical nurse specialists
and nutritional support. Some of this depends on the fur-
ther allocation of scarce resources but some aspects, such
as ensuring all patients are discussed with a member of the
specialist multidisciplinary team and are screened for mal-
nutrition, can be improved by relatively simple changes in
practice.
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